Evidence map›Paper›PMID 37600966›Full record

ArticleAdvanced materials technologies2023

Cell therapy biomanufacturing: integrating biomaterial and flow-based membrane technologies for production of engineered T-cells.

Kartik Bomb, Paige J LeValley, Ian Woodward, Samantha E Cassel, Bryan P Sutherland, Arnab Bhattacharjee, Zaining Yun, Jonathan Steen, Emily Kurdzo, Jacob McCoskey and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials technologies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kartik BombChemical and Biomolecular Engineering, University of Delaware, Newark, DE.
Paige J LeValleyChemical and Biomolecular Engineering, University of Delaware, Newark, DE.
Ian WoodwardChemical and Biomolecular Engineering, University of Delaware, Newark, DE.
Samantha E CasselChemical and Biomolecular Engineering, University of Delaware, Newark, DE.
Bryan P SutherlandChemical and Biomolecular Engineering, University of Delaware, Newark, DE.
Arnab BhattacharjeeMechanical Engineering, University of Delaware, Newark, DE.
Zaining YunChemical and Biomolecular Engineering, University of Delaware, Newark, DE.
Jonathan SteenEMD Millipore Corporation, Bedford, MA, an affiliate of Merck, Newark, DE.
Emily KurdzoEMD Millipore Corporation, Bedford, MA, an affiliate of Merck, Newark, DE.
Jacob McCoskeyEMD Millipore Corporation, Bedford, MA, an affiliate of Merck, Newark, DE.
David BurrisMechanical Engineering, University of Delaware, Newark, DE.
Kara LevineEMD Millipore Corporation, Bedford, MA, an affiliate of Merck, Newark, DE.
Christina CarbrelloEMD Millipore Corporation, Bedford, MA, an affiliate of Merck, Newark, DE.
Abraham M LenhoffChemical and Biomolecular Engineering, University of Delaware, Newark, DE.
Catherine A FromenChemical and Biomolecular Engineering, University of Delaware, Newark, DE.ORCID 0000-0002-7528-0997
April M KloxinChemical and Biomolecular Engineering, University of Delaware, Newark, DE.ORCID 0000-0002-4594-2953

Funding

Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI Anjana Narayan Bhat · 2012 to 2026
$67.2M
This renovation project will create over 1455 sq. ft. of state- of-the-art reseaP20GM104316 · NIGMS · UNIVERSITY OF DELAWARE · PI FOX, JOSEPH M · 2014 to 2024
$26.8M
Understanding synovial macrophage inflamm-aging within osteoarthritisP20GM139760 · NIGMS · UNIVERSITY OF DELAWARE · PI DAWN M ELLIOTT · 2021 to 2026
$19.1M
Pilot Research Subproject ProgramP30GM110758 · NIGMS · UNIVERSITY OF DELAWARE · PI BEEBE, THOMAS PAUL · 2014 to 2018
$5.8M
NIGMS NIH HHS P20 GM103446NIGMS NIH HHS P20 GM104316NIGMS NIH HHS P20 GM139760NIGMS NIH HHS P30 GM110758
6 · The paper itself

Abstract

Adoptive T-cell therapies (ATCTs) are increasingly important for the treatment of cancer, where patient immune cells are engineered to target and eradicate diseased cells. The biomanufacturing of ATCTs involves a series of time-intensive, lab-scale steps, including isolation, activation, genetic modification, and expansion of a patient's T-cells prior to achieving a final product. Innovative modular technologies are needed to produce cell therapies at improved scale and enhanced efficacy. In this work, well-defined, bioinspired soft materials were integrated within flow-based membrane devices for improving the activation and transduction of T cells. Hydrogel coated membranes (HCM) functionalized with cell-activating antibodies were produced as a tunable biomaterial for the activation of primary human T-cells. T-cell activation utilizing HCMs led to highly proliferative T-cells that expressed a memory phenotype. Further, transduction efficiency was improved by several fold over static conditions by using a tangential flow filtration (TFF) flow-cell, commonly used in the production of protein therapeutics, to transduce T-cells under flow. The combination of HCMs and TFF technology led to increased cell activation, proliferation, and transduction compared to current industrial biomanufacturing processes. The combined power of biomaterials with scalable flow-through transduction techniques provides future opportunities for improving the biomanufacturing of ATCTs.

Indexed as

adoptive T-cell therapybiomanufacturingbiomaterialstangential flow filtration

Identifiers

PMID37600966
PMCPMC10437131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.